In 2021 the investment in funding more than 1,200 clinical trials of personalised cell and gene therapies worldwide is an indicator of the progression in this modality that looks to treat life-threatening cancers, cardiovascular diseases, and genetic disorders.
The key to ATMP manufacturing is flexibility, flexibility in terms of adherence to the requirements for regulatory approval and commercial scale-out by adapting their solutions to incorporate emerging technologies to facilitate the evolving complexity of new compounds.
Download our ATMP manufacturing capabilities sheet to find out more about how Symbiosis are well placed to support your ATMP manufacturing requirements.
Fill in your details to be added to our mailing list and receive our latest updates.
